Hong Kong-based Prenetics Global Limited is buying a majority stake in ACT Genomics, a Nasdaq-listed company specialising in precision oncology in Asia, as it looks to build an ecosystem extending beyond COVID-19 testing.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
